Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study

Autor:	Martin Hellmich, Stephan Rosenkranz, Tilmann Kramer, Kristiana Natsina, Felix Gerhardt, Henrik ten Freyhaus, Daniel Dumitrescu, Thomas Viethen, Max Wissmüller, Stephan Baldus
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Adult Male medicine.medical_specialty medicine.medical_treatment Iron Diseases of the musculoskeletal system Ferric Compounds Gastroenterology FERRIC CARBOXYMALTOSE Targeted therapy Physiology (medical) Internal medicine medicine Pulmonary arterial hypertension (PAH) Humans Orthopedics and Sports Medicine Maltose Adverse effect Aged Retrospective Studies Pulmonary Arterial Hypertension Anemia Iron-Deficiency biology medicine.diagnostic_test Transferrin saturation business.industry Iron deficiency QM1-695 Original Articles Iron Deficiencies Middle Aged medicine.disease Ferric carboxymaltose Ferritin RC925-935 Human anatomy biology.protein Serum iron Original Article Female business Progressive disease
Zdroj:	Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 6, Pp 1501-1512 (2021) Journal of Cachexia, Sarcopenia and Muscle
ISSN:	2190-5991 2190-6009
Popis:	Background Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates with disease severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral iron on clinical measures warrants further investigation. Methods We retrospectively analysed the long‐term effects of intravenous ferric carboxymaltose (FCM) on iron status and clinical measures in patients with PAH and ID [ferritin
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2aac04c3fd2588a7abb9cc7280412c5 https://doaj.org/article/4e91b779634644a49a0e1fdf6e4742a9 Zobrazit plný text záznamu Plný text